A new peer-reviewed paper co-authored by Theertha Biopharma has been published in Current Microbiology (27 December 2025): “Microbial Systems Enhancing CAR-Based Therapies: A Synthetic Biology Paradigm for Next-Generation Cancer Immunotherapy.”
The work explores how engineered microbial systems can enhance chimeric antigen receptor (CAR) based therapies — part of a growing body of synthetic-biology thinking that could broaden and de-risk next-generation cancer immunotherapy.
Authored by Sameer Kumar Singdevsachan (Theertha Biopharma Pvt. Ltd.), with collaborators at Hoynoza Technologies and the Manipal Centre for Biotherapeutics Research.
Read the paper: DOI 10.1007/s00284-025-04679-z · PMID 41454921. See more on our Publications & Patents page.